Downregulation of PGC-1α Prevents the Beneficial Effect of EET-Heme Oxygenase-1 on Mitochondrial Integrity and Associated Metabolic Function in Obese Mice

Shailendra P. Singh, Lars Bellner, Luca Vanella, Jian Cao, John R. Falck, Attallah Kappas, and Nader G. Abraham

1New York Medical College, Departments of Medicine and Pharmacology, Valhalla, NY, USA
2Department of Drug Science, Section of Biochemistry, University of Catania, Catania, Italy
3First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China
4Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA
5The Rockefeller University, New York, NY, USA

Correspondence should be addressed to Nader G. Abraham; nader_abraham@nymc.edu

Received 24 August 2016; Revised 13 October 2016; Accepted 10 November 2016

A cademicEdi to r:C.S. Johsto n

Copyright © 2016 Shailendra P. Singh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background/Objectives. Obesity and metabolic syndrome and associated adiposity are a systemic condition characterized by increased mitochondrial dysfunction, inflammation, and inhibition of antioxidant genes, HO-1, and EETs levels. We postulate that EETs attenuate adiposity by stimulating mitochondrial function and induction of HO-1 via activation of PGC-1α in adipose and hepatic tissue. Methods. Cultured murine adipocytes and mice fed a high fat (HF) diet were used to assess the functional relationship among EETs, PGC-1α, HO-1, and mitochondrial signaling using an EET-agonist (EET-A) and PGC-1α-deficient cells and mice using lentiviral PGC-1α(sh). Results. EET-A is a potent inducer of PGC-1α, HO-1, mitochondrial biogenesis (cytochrome oxidase subunits 1 and 4 and SIRT3), fusion proteins (Mfn 1/2 and OPA1) and fission proteins (DRP1 and FIS1) (p < 0.05), fasting glucose, BW, and blood pressure. These beneficial effects were prevented by administration of lenti-PGC-1α(sh). EET-A administration prevented HF diet induced mitochondrial and dysfunction in adipose tissue and restored VO2 effects that were abrogated in PGC-1α-deficient mice. Conclusion. EET is identified as an upstream positive regulator of PGC-1α that leads to increased HO-1, decreased BW and fasting blood glucose and increased insulin receptor phosphorylation, that is, increased insulin sensitivity and mitochondrial integrity, and possible use of EET-agonist for treatment of obesity and metabolic syndrome.

1. Introduction

Obesity is a global epidemic and a major risk factor in the development of metabolic syndrome and diabetes associated complications such as cardiovascular disease, kidney disease, hypertension, and neuropathies [1–3]. Epoxyeicosatrienoic acids (EETs) are arachidonic acid derived metabolites generated by a family of cytochrome P450 (CYP) monooxygenases and epoxygenases [4, 5]. EETs are rapidly hydrolyzed by ROS and by soluble epoxide hydrolase (sEH) to their respective dihydroxyepoxytriienoic acids [6–8]. EET agonists prevent both adiposity and vascular complications both in vitro and in vivo and obesity-induced adipose tissue expansion impairs the CYP epoxygenase pathway and the generation of EET in vivo [9–12]. Mitochondrial biogenesis, oxygen consumption, and oxidative phosphorylation are regulated by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [13], which in turn is regulated by posttranslational modifications, including phosphorylation and deacetylation by AMPK and SIRT1, respectively [14]. PGC-1α activates several key components of the adaptive thermogenesis program, including the stimulation of energy uptake, and mitochondrial fatty acid oxidation. Transgenic mice with mildly
2. Materials and Methods

2.1. Animal Experimentation and Generation of Lentiviral Vector-Mediated PGC-1α Deficient Mice. All animal experiments followed a PLa, General Hospital, Beijing, China, and NYMC IACUC institutionally approved protocol in accordance with the NIH Guidelines. Male C57BL6 mice were used in the studies. Two separate experiments (A and B) were performed. In the first experiment (A) we investigated the effect of PGC-1α ablation and short-term EET-A treatment of mice fed a HF diet for 8 weeks. In the second experiment (B) we examined the effect of an EET-A regimen in mice fed a HF diet for 24 weeks: for experiment (A) with PGC-1α-deficient mice, animals were divided into 4 groups: (1) lean, (2) HFD, (3) HFD+EET-analog [EET-A is sodium (S,Z)-2-((3-pentylureido)tridec-8-enamido)succinate], and (4) HFD+EET-A+PGC-1α lentivirus. Lean mice (group 1) were fed ad libitum a normal chow diet containing 11% fat, 62% carbohydrate, and 27.0% protein with total calories of 12.6 KJ/g. The remaining animals (groups 2, 3, and 4) were fed a HF diet containing 58% fat (from lard), 25.6% carbohydrate, and 16.4% protein with total calories of 23.4 KJ/g (Harlan, Teklad Lab Animal Diets, US) for 8 weeks. Mice were treated as follows: group (1) was fed normal chow diet, group (2) was fed HF diet, group (3) was injected with EET-A, intraperitoneally, every other day for 4 weeks at a dose of 1.5 mg/100 gm of body weight, and group (4) received a 2-bolus injection of PGC-1α(sh) lentivirus (Dharmacon, Lafayette, CO) injected into the retroorbital vein at a concentration of 40–70 × 10⁶ TU/mouse in 80–100 μl and received EET-A injections identical to group 3.

For the second experiment (long-term effect of EET-agonist) (B) mice were divided into three groups similar to groups 1, 2, and 3 in experiment (A) but were maintained on the diets for 24 weeks and group (3) received injections with EET-A every other day for the last 8 weeks of the experiment.

For fasting blood glucose level measurement mice were fasted for 6 h with access to water, after blood was obtained from tail and blood glucose concentration was determined with the Accuchek Advantage gluometer (Roche, Madison, WI). At the end of the experimental period, mice were anesthetized with sodium pentobarbital (65 mg/Kg, i.p.) and, at the time of sacrifice, body weight was measured.

2.2. Cell Culture. 3T3-L1 murine preadipocytes were purchased from ATCC (ATCC, Manassas, VA). After thawing, 3T3-L1 cells were cultured at 37°C in a 5% CO₂ incubator in α-minimal essential medium (α-MEM, Invitrogen, Carlsbad CA) supplemented with 10% heat inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) and 1% antibiotic/antimycotic solution (Invitrogen, Carlsbad, CA). The medium was changed after 48 h and every 3-4 days thereafter as described previously [10]. For adipogenesis studies the medium was replaced with adipogenic medium (Dulbecco’s modified Eagle Medium (DMEM) with high glucose (Invitrogen), supplemented with 10% (v/v) FBS, 10 μg/ml insulin (Sigma-Aldrich, St. Louis, MO), 0.5 mM dexamethasone (Sigma-Aldrich), and 0.1 mM indomethacin (Sigma-Aldrich) and the cells were cultured for an additional 8 days. Cells were
cultured in the absence and presence of EET-A at a dose of 10 μM. At the experimental endpoints, cells were collected by trypsinization, washed once with PBS, and then lysed for protein measurements and for RNA extraction.

2.3. Generation of Lentiviral Vector-Mediated PGC-1α Deficient 3T3-L1 Derived Adipocytes. SMART vector lentiviral shRNA-PARGC1A or scrambled RNA (Dharmacon, Lafayette, CO) was applied to 3T3-L1 cells to establish a stably transduced cell line. Briefly, 1 × 10⁶ cells were seeded in 6-well plates 1 day prior to transduction. On the day of transduction, the transduction medium was made by 1 × 10⁶ transducing units (TU) of lentiviral particles with 0.5 ml α-MEM growth medium being applied to each well and incubated for 3 h to maximize the contact between each cell and lentiviral particles. Cells were also treated with the transduction medium without lentiviral particles which served as untransduced control. Growth medium (1.5 ml) was then added to each well in the presence of 8 μg/ml polybrene (final concentration). After 48 h incubation, antibiotic selection medium (α-MEM growth medium with 10 μg/ml puromycin) was used to kill all the untransduced cells. Cells were then cultured and maintained as outlined above.

2.4. RNA Extraction and Real-Time PCR. Total RNA was extracted from 3T3 cells using TRizol® (Ambion, Austin, TX) and from frozen adipose tissue by RNeasy® Lipid Tissue (Qiagen), as per instructions provided by the manufacturers. RNA was determined by measuring the absorbance at 260 nm (A260) with a Biotek plate reader and the Take3™ plate (Biotek, Winooski, VT), and assessed by the A260/A280 ratio. cDNA was synthesized from total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Total RNA was extracted from 3T3 cells using TRIzol® Reagent (Invitrogen, Carlsbad, CA) and from frozen adipose tissue by RNeasy Lipid Tissue (Qiagen), as per instructions provided by the manufacturer. Total RNA was extracted from 3T3 cells using TRIzol® Reagent (Ambion, Austin, TX) and from frozen adipose tissue by RNeasy® Lipid Tissue (Qiagen), as per instructions provided by the manufacturers. RNA was determined by measuring the absorbance at 260 nm (A260) with a Biotek plate reader and the Take3 plate (Biotek, Winooski, VT), and assessed by the A260/A280 ratio. cDNA was synthesized from total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), after real-time PCR was performed using TaqMan® Fast Universal Master Mix (2x), on a 7500HT Fast Real-Time PCR System (Applied Biosystems). Specific TaqMan Gene Expression Assays probes for mouse HO-1, PGC1α, COX-IV (cytochrome c oxidase subunit-IV), adiponectin, TNFα, IL-6, Mfn1, Mfn2, Drp1, Fisl, OA, PAI, p2, SIRT3, C/EBPα, and GAPDH were used as previously described [33].

2.5. Western Blot Analysis. Frozen mouse adipose tissue was ground under liquid nitrogen and suspended in homogenization buffer (mmol/l: 10 phosphate buffer, 250 sucrose, 1.0 EDTA, 0.1 PMSF, and 0.1% v/v tertigol, pH 7.5). For in vitro western blot analysis pelleted cells were lysed with lysis buffer supplemented with protease and phosphatase inhibitors (Complete™ Mini and PhosSTOP™, Roche Diagnostics, Indianapolis, IA). Immunoblotting for HO-1, SIRT1, UCP1, TFAM, p2, PEG1/MEST, MnSOD, AMPK, pAMPK, AKT, pAKT, FAS, and PGC-1α and phosphorylation of insulin receptors (IR) IRp972, IRp1146, COX-IV, adiponectin, β-actin, and GAPDH were performed as previously described [8, 34].

2.6. Oxygen Consumption. Oxygen consumption (VO₂) and carbon dioxide production (VCO₂) were measured using the Oxylet gas analyzer and air flow unit (Panlab-Bioseb, Vitrolles, France). Animals were allowed to acclimatize in the oxygen consumption chambers for 2 hours three times a week for 3 weeks prior to the recording of data. Mice were placed in the Oxylet chamber and the flow rate was adjusted and the dCO₂ maintained between 0.4 and 0.8 as per the instructions provided by the manufacturer, after the hourly respiratory quotients were calculated based on the VO₂ and VCO₂ obtained by the gas analyzer. Individual readings were recorded twice per mouse. The data for VO₂ are expressed as the consumed volume of oxygen per kilogram body weight per minute (ml/kg/min). The respiratory quota is expressed as CO₂ eliminated divided by the O₂ consumed.

2.7. Statistical Analysis. Data are expressed as means ± SEM. Significance of difference in mean values was determined using one-way analysis of variance followed by the Bonferroni posttest for comparison between groups. p < 0.05 was considered to be significant.

3. Results

3.1. Effect of EET-A on Mitochondrial Fission (DRP1 and Fis1) and Fusion (Mfn1 and Mfn2) in Wildtype and Lentiviral shRNA Vector-Mediated PGC-1α Deficient 3T3-L1-Derived Adipocytes. To examine whether EET-A can modulate the mitochondrial fission-to-fusion ratio through PGC-1α we knocked down PGC-1α in 3T3-L1 adipocyte cells using lentivirus vector carrying target specific shRNA. RT-PCR data show more than 80% inhibition of PGC1α mRNA levels after transduction with PGC-1α shRNA (Figure 1(a)) and a concomitant decrease in HO-1 mRNA expression (Figure 1(b)). PGC-1α knockdown resulted in increased mRNA expression of Fisl (p < 0.05) as compared to WT cells. The mRNA expression of DRP1 was not affected by PGC-1α silencing. While EET-A did not affect fusion related expression in WT cells (Figures 1(c) and 1(d)), the Mfn2 levels were elevated (p < 0.05) in WT cells treated with EET-A as compared to WT control cells. The mRNA levels of OPA1 were not increased by EET-A (Figure 1(e)). PGC-1α silencing decreased (p < 0.05) Mfn2 and OPA1 mRNA expression as compared to WT control cells. Importantly, EET-A had no effect on Mfn2 or OPA1 mRNA expression levels in PGC-1α deficient cells (Figures 1(e) and 1(f)).

The mRNA expression levels of SIRT3 and COX-1 were decreased (p < 0.05) in the PGC-1α knockdown cells as compared to WT cells. While EET treatment had only moderate effect on the expression of SIRT1, SIRT3, and COX-1 in WT cells, the expression of these genes were not affected by EET-A treatment of PGC-1α deficient cells (Figures 1(g), 1(h), and 1(i)).

3.2. Effect of Short- versus Long-Term EET-A on Body Weight, Blood Pressure, Fasting Blood Glucose, Oxygen Consumption, and Respiratory Quotient. We examined the effect of EET-A on body weight, blood pressure, fasting blood glucose, O₂ consumption, and the ratio of CO₂/O₂ in mice fed a HF diet for 8 and 24 weeks (Figure 2). As expected, mice on a HF diet displayed a decrease (p < 0.05) in VO₂ consumption.
Figure 1: Effect of EET-A treatment on WT and PGC-1α-deficient 3T3-L1 adipocytes cells on gene expression related to mitochondrial biogenesis and dynamics. mRNA expression of PGC-1α (a), HO-1 (b) in WT and PGC-1α deficient 3T3-L1-derived adipocyte cells, and DRP1 (c), Fis1 (d), OPA1 (e), Mfn2 (f), SIRT1 (g), SIRT3 (h), and COX-I (i) in WT and PGC-1α deficient 3T3-L1-derived adipocyte cells in the absence and presence of EET-A (10 μM) treatment. Results are mean ± SE, n = 3-4, *p < 0.05 versus WT, **p < 0.01 versus WT, #p < 0.05 versus WT, and ##p < 0.05 versus WT-EET-A. White bars: WT; black bars: PGC-1α deficient cells.
However, HF diet fed mice treated with EET-A exhibited an increase ($p < 0.05$) in oxygen consumption with concomitant lowering of $\text{VCO}_2/\text{VO}_2$. Importantly, EET-A had no effect on oxygen consumption or respiratory quotient in HF diet fed PGC-1α deficient mice (Table 1). Fasting blood glucose levels and blood pressure were increased in mice fed a HF diet as compared to control animals (Table 1, $p < 0.05$). Importantly, fasting blood glucose levels were normalized in mice fed a HF diet and treated with EET-A ($p < 0.01$) when compared to lean mice. The EET-A mediated decrease in fasting blood glucose levels was prevented in PGC-1α deficient animals fed a HF diet. Importantly, regardless of the duration, EET-A treatment normalized all four metabolic parameters (Table 1).

3.3. Effect of Short-Term EET-A on the Expression of Mitochondrial Fission (DRP1 and Fis1) and Fusion (Mfn1, Mfn2) in Adipose Tissue of High Fat Diet Fed Control and PGC-1α Deficient Mice. PGC-1α mRNA expression in HF diet fed mice treated with vehicle (Veh) solution ($\text{H}_2\text{O}$) was reduced ($p < 0.05$) as compared to lean mice. Importantly EET-A treatment nullified the inhibitory effect of HF diet on PGC-1α expression. EET-A treatment of PGC-1α-deficient mice had no effect on PGC-1α mRNA expression (Figure 3(a)). The mRNA expression levels of mitochondrial fission related DRP1 and Fis1 in adipose tissue were increased ($p < 0.05$) by a HF diet. Interestingly, EET-A treatment of mice on a HF diet decreased ($p < 0.05$) the adipose tissue levels of both DRP1
Table 1: (a) EET-agonist treatment (4 weeks) WT and Ln PGC-1α(sh) mice. Body weights, fasting blood glucose, blood pressure, oxygen consumption, and respiratory quotient of mice fed regular chow or HF diet for 8 weeks. EET-A administered for the last 4 weeks. (b) EET-agonist treatment (8 weeks) WT mice. Body weights, blood glucose, oxygen consumption, and respiratory quotient of mice fed regular chow or HF diet for 24 weeks. EET-A administered for the last 8 weeks.

(a)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lean</th>
<th>HF</th>
<th>HF+EET-A</th>
<th>HF+EET-A+Ln PGC-1α(sh)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (g)</td>
<td>25.8 ± 0.35</td>
<td>30.2 ± 0.85*</td>
<td>23.9 ± 0.19*</td>
<td>29.0 ± 1.47**</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>107.5 ± 4.84</td>
<td>209.5 ± 9.84*</td>
<td>156.0 ± 11.06*</td>
<td>263.5 ± 21.71**</td>
</tr>
<tr>
<td>BP (mm Hg)</td>
<td>104.0 ± 1.34</td>
<td>148.2 ± 3.01*</td>
<td>1.05 ± 1.11 ±</td>
<td>137.0 ± 2.33**</td>
</tr>
<tr>
<td>VO₂ (ml/kg/min)</td>
<td>53.92 ± 2.82</td>
<td>45.54 ± 1.82*</td>
<td>77.17 ± 3.38*</td>
<td>46.46 ± 3.72**</td>
</tr>
<tr>
<td>RQ (CO₂/O₂)</td>
<td>0.74 ± 0.003</td>
<td>0.77 ± 0.007*</td>
<td>0.74 ± 0.01*</td>
<td>0.78 ± 0.003**</td>
</tr>
</tbody>
</table>

Values are means ± SEM of 6 mice per group. Differences at *p < 0.05 versus lean, **p < 0.05 versus HF+EET-A. Body weight (BW), Blood pressure (BP). Fasting blood sugar (FBS). Oxygen consumption (VO₂). Respiratory quotient (RQ).

(b)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lean</th>
<th>HF</th>
<th>HF+EET-A</th>
<th>HF+EET-A+Ln PGC-1α(sh)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (g)</td>
<td>28.68 ± 1.21</td>
<td>56.63 ± 0.88*</td>
<td>32.43 ± 0.83*</td>
<td>32.43 ± 0.83*</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>109.5 ± 4.84</td>
<td>286 ± 8.11*</td>
<td>100.2 ± 11.32*</td>
<td>100.2 ± 11.32*</td>
</tr>
<tr>
<td>BP (mm Hg)</td>
<td>105.8 ± 2.87</td>
<td>156.7 ± 6.87*</td>
<td>113.5 ± 4.44*</td>
<td>113.5 ± 4.44*</td>
</tr>
<tr>
<td>VO₂ (ml/kg/min)</td>
<td>56.2 ± 2.65</td>
<td>33.77 ± 1.19*</td>
<td>579.5 ± 3.12*</td>
<td>579.5 ± 3.12*</td>
</tr>
<tr>
<td>RQ (CO₂/O₂)</td>
<td>0.73 ± 0.006</td>
<td>0.8 ± 0.01*</td>
<td>0.75 ± 0.007*</td>
<td>0.75 ± 0.007*</td>
</tr>
</tbody>
</table>

Values are means ± SEM of 3–5 mice per group. Differences at *p < 0.05 versus lean, **p < 0.05 versus HF. Body weight (BW). Fasting blood sugar (FBS). Blood pressure (BP). Oxygen consumption (VO₂). Respiratory quotient (RQ).

and Fis1 as compared to HF diet fed mice. Inversely, DRP1 and Fis1 mRNA levels VAT of PGC1α-deficient mice were increased (p < 0.05) as compared to HF diet fed mice treated with EET-A alone (Figures 3(b) and 3(c)). The expression levels of fusion related Mfn1 and Mfn2 were significantly decreased by a HF diet in adipose tissue. Prominently, EET-A treatment of mice on a HF diet increased (p < 0.05) the expression of both Mfn1 and Mfn2 as compared to HF diet fed mice (Figures 3(d) and 3(e)). The expression level was PGC1α-dependent as the levels of both Mfn1 and Mfn2 increased in adipose tissue from PGC1α-deficient mice (p < 0.05) compared to HF diet fed mice treated with EET-A alone (Figures 3(d) and 3(e)).

3.4. Effect of Long-Term EET-A on Insulin Receptor Phosphorylation and pAMPK and pAKT Levels in Adipose Tissue of Mice Fed a HF Diet. Mice fed a HF diet had a decrease (p < 0.05) in the protein expression of Iρp-Tyr 972, Iρp-Tyr 1146, pAMPK, and pAKT. Mice fed a HF diet and treated with EET-A displayed an 8.2-fold increase (p < 0.001) in Iρp-Tyr 972 and a 7.3-fold increase in Iρp-Tyr 1146 (p < 0.01) as compared to mice fed a HF diet alone (Figure 4). Likewise, EET-A increased the pAKT/AKT and pAMPK/AMPK ratio (p < 0.05) when compared to mice fed a HF diet alone (Figure 4).

3.5. Effect of EET-A on Induction of HO-1, PGC1α, SIRT1, and Adiponectin Expression in Adipose Tissue of Mice Fed a HF Diet. Western blot analysis demonstrated that mice fed a HF diet for 24 weeks had decreased levels of HO-1 protein expression (Figure 5) as compared to mice fed a normal chow diet. Treatment with EET-A for 8 weeks resulted in a 16-fold increase (p < 0.01) in HO-1 protein expression as compared to mice fed a HF diet alone (Figures 5(a) and 5(e)). Visceral adipose tissue obtained from mice fed a HF diet exhibited a decrease (p < 0.05) in PGC1α, SIRT1, and adiponectin expression as compared to lean mice fed a regular chow diet, while EET-A increased (p < 0.05) PGC1α, SIRT1, and adiponectin expression levels as compared to the mice fed a HF diet alone (Figure 5).

3.6. Effect of EET-A on TFAM, UCPI, and MnSOD Levels in Adipose Tissue of Mice Fed a HF Diet. Our analysis demonstrated a decrease (p < 0.05) in the UCPI, TFAM, and MnSOD expression levels in adipose tissue of mice fed a HF diet as compared to lean mice fed a regular chow diet. EET-A increased (p < 0.05) MnSOD, UCPI, and TFAM expression as compared to mice fed a HF diet alone (Figure 6). mRNA expression of COX-IV was elevated in obese mice treated with EET-A (group 3) (p < 0.05) (Figure 6). We examined the effect of EET-A treatment on body and fat appearance. EET-A-treatment visibly reduced weight gain in mice fed HFD (Figure 2(a)), an effect that was prevented in PGC1α-deficient mice. The final weights after 4 or 8 weeks of vehicle or EET-A treatment are presented in Table 1. The EET-A-mediated reduction of weight gain was observed as early as after 4 weeks. As seen in Figure 2(b), visceral fat in control mice fed HFD was decreased by EET-A-treatment, but this EET-A-mediated effect was prevented in PGC1α-deficient mice.

3.7. EET-A Decreases Expression of Adipogenic and Inflammatory Mediators in Adipose Tissue of Mice Fed a HF Diet. A HF diet increased (p < 0.05) the expression of adipogenic
Figure 3: Effect of short-term EET-A treatment on the expression of genes related to mitochondrial biogenesis and dynamics in the adipose tissue of mice. mRNA expression of PGC-1α (a), Drp1 (b), Fis1 (c), and Mfn1 (d) and protein expression of Mfn2 (e) in the adipose tissues of lean, HF diet fed (HF), HF diet EET-A-treated (EET-A), and PGC-1α-deficient (Ln shPGC-1α) mice. Results are mean ± SE, n = 3-4, *p < 0.05 versus lean, #p < 0.05 versus HF, and ##p < 0.05 versus HF+EET.
Figure 4: Effect of short-term EET-A treatment on insulin receptor phosphorylation and AKT and AMPK signaling in adipose tissue of mice fed HF diet. (a) Representative western blots and ((b) to (f)) densitometry analyses of WBs in adipose tissue of mice; (b) insulin receptor phosphorylation IRp-Tyr-972; (c) insulin receptor phosphorylation IRp-Tyr-1146; (d) phosphorylated protein kinase B (pAKT); (e) phosphorylated adenosine monophosphate protein kinase (pAMPK) proteins in mice fed a normal diet lean and mice fed a high fat (HF) diet treated with EET-A. Results are mean ± SE, n = 4, *p < 0.05 versus lean, and #p < 0.05 versus HF.

4. Discussion

This study demonstrates that EET participates in the regulation of mitochondrial function in adipocyte cells in vitro.
and in adipose and hepatic tissues in vivo by influencing the levels of PGC-1α and HO-1 expression. We show that EET is upstream of PGC-1α and that contributes to increased mitochondrial biogenesis, function, and fusion potential, leading to an improvement of metabolic parameters in obese mice that is PGC-1α dependent. EET was effective in the restoration of mitochondrial integrity in the early stage of obesity (8 weeks) as well as in chronic obesity (24 weeks). The following key findings substantiate this conclusion.

Firstly we show that lentiviral vector-mediated knock-down of PGC-1α cultured murine adipocytes in vitro increases the mitochondrial fission potential (DRP1 and Fis1) at the expense of mitochondrial quality control and fusion potential (OPA1, Mfn2) as well as reducing the expression of genes involved in oxidative phosphorylation and suppression of ROS (COX-1, SIRT1, and SIRT3). While treatment of WT adipocytes with EET-agonist had a beneficial effect on the mitochondrial function and fusion potential, these effects were absent in PGC-1α-deficient adipocytes.

In vivo, a HF diet precipitated increased expression of the genes regulating mitochondrial fission, while concomitantly reducing the expression of the genes responsible for mitochondrial quality control and fusion processes in visceral adipose tissue as compared to mice fed a regular
chow diet. EET-agonist treatment of mice fed a HF diet resulted in a reduction in mitochondrial fission potential and a normalized or an enhanced expression of mitochondrial fusion-associated genes. Moreover, while the expression of PGC-1α in obese mice was reduced when compared to lean mice, the levels of PGC-1α in HF diet fed mice treated with an EET-agonist were higher than in both lean mice and mice fed a HF diet alone. Importantly, global knockdown of PGC-1α in mice fed a HF diet nullified the EET-A-mediated beneficial effects on mitochondrial fusion and ROS suppressing potential in visceral adipose tissue. Increasing HF intake has been shown to enhance free fatty acid generation and increase mitochondrial dysfunction and ROS [35–38]. Together, these results clearly indicate that a recruitment of PGC-1α is crucial to the beneficial effects of the EET-agonist on mitochondrial function and on the reduction of fission and increase of fusion-associated processes in both adipose and hepatic tissues.

Our observation linking EETs to mitochondrial viability and fusion potential is supported by the demonstration that EETs protect neurons from oxidative damage while stimulating mitochondrial biogenesis [39]. Approximately 90% of cellular ROS are generated by the mitochondria and contribute to the mitochondrial energy metabolism [23]. SIRT3 is important in ROS suppression, mitochondrial biogenesis, and metabolic homeostasis, including mitochondrial fatty acid oxidation, and the target of PGC-1α [23, 24]. Multiple studies have reported the importance of mitochondrial function and dynamics in health and aging; for review see [28]. Knockout mice of Mfn1, Mfn2, and OPA1 are all embryonic lethal [40] and mutations in OPA1 in humans are associated with hereditary blindness, while Mfn2 mutations are the cause of Charcot-Marie-Tooth disease [27, 40, 41]. Since mitochondrial integrity encompasses the balance between mitochondrial fusion and fission [42, 43], an increase of Mfn1 and Mfn2 or decrease in fusion DRP1 and fissionis an indication of mitochondrial integrity and less oxidative stress that is responsible for mitochondrial damage and subsequent clearance by mitophagy [44].

This is in agreement with our data that showed liver-specific knockout of Mfn2 in mice is linked to impaired glucose metabolism, to decreases in SIRT1, SIRT3, and insulin signaling resulting in hepatic steatosis [45]. Thus, we show a PGC-1α-dependent increase of HO-1 expression, thereby
Figure 7: Effect of high fat diet and long-term treatment with EET-A on protein and mRNA expression of adipogenic markers and inflammatory cytokines. (a) Representative Western blots of FAS, aP2, and MEST proteins. Densitometric analyses of (b) FAS and (c) MEST proteins. (d) Protein and (e) mRNA levels of aP2. (f) C/EBPα, (g) TNF-α, and (h) IL-6 mRNA levels. Data are normalized to β-actin for protein or GAPDH for mRNA. Results are mean ± SE, n = 4, *p < 0.05 versus lean, and #p < 0.05 versus lean-HF.

potentiating the beneficial effect of PGC-1α itself. These results are supported by the demonstration that doxorubicin-induced oxidative stress increased mitochondrial fragmentation and Fis1 expression, causing mitophagy and mitochondrial fragmentation, an effect that was prevented by increased levels of HO-1 favoring expression of Mfn1 and Mfn2 [46].

Furthermore, we report that short- and long-term treatment with EET-A normalized impaired insulin receptor phosphorylation and decreased fasting blood glucose, BW, VO₂, and RQ in mice fed a HF diet. The increase in VO₂ may be related to an EET-mediated alternate metabolic strategy of HF-fed mice, that is, to increase the metabolic rate in response to increased EET-A-mediated PGC-1α expression and mitochondrial function leading to a reprogramming of adipose stem cells to brown-like cells, thus allowing the recovery of homeostatic control and the subsequent decrease in body fat, increase in insulin sensitivity, and normalization of oxygen consumption. Further, in agreement with our results an increase of PGC-1α is associated with the mechanism controlling mitochondrial biogenesis and integrity [47] and increased insulin sensitivity [16]. Increase of insulin receptor phosphorylation as a result of activation of HO-1 gene expression by EET-agonist is responsible for control of adiposity and insulin sensitivity (reviewed in [18, 48]).
This supports the hypotheses linking EET-A, the increase of PGC-1α, mitochondrial fusion, SIRT1, pAMPK, and HO-1 expression to a metabolic adipocyte reprogramming that may influence adipocyte hemostasis and delay terminal differentiation as evidenced by a decrease in Pegl/MEST and an increase in insulin receptor phosphorylation and adiponectin downstream signaling, including pAMPK. AMPK is as a master regulator of energy expenditure and performs its actions based on changes in the intracellular AMP/ATP ratio [49]. In metabolic organs, such as the liver, adipose tissues, and skeletal muscle, activated AMPK stimulates catabolic processes, while inhibiting anabolic AMPK [50]. As AMPK through its energy expenditure regulation also impacts the cellular redox balance of NAD⁺ and NADPH it can also activate SIRT1 deacetylation-activity, which is dependent on cellular NAD⁺ levels [51]; meanwhile several actions of AMPK have been shown to be dependent on SIRT1 activity [52]. AMPK and SIRT1 regulate PGC-1α activity through phosphorylation and deacetylation, respectively, and together AMPK, SIRT1, and PGC-1α control a wide range of metabolic processes, including insulin receptor signaling and gluconeogenesis in the liver, adipocyte browning and thermogenesis, and mitochondrial biogenesis [50, 51, 53]. EET-A increased pAMPK and SIRT1 levels in both adipose and liver tissues of HF diet fed mice corroborating the EET-mediated increase in total body oxygen consumption.

The importance of PGC-1α in adipose tissue has been established in mice lacking PGC-1α specifically in adipocytes which develop insulin resistance and have increased circulating lipid levels when fed a HF diet [16]. PGC-1α control of energy homeostasis suggests a role as a target for both antiobesity and diabetes drugs [54]. The finding that EET-A restored oxygen consumption and respiratory quotient to levels found in lean mice is supported by the beneficial increase in PGC-1α, SIRT1, pAMPK, and COX-IV (a unit of the mitochondrial OXPHOS complex) in the adipose tissue of mice fed a HF diet and treated with EET-A, thus highlighting the role of EETs in mitochondrial energy production and expenditure. EET-A increased PGC-1α expression in both adipose and hepatic tissue of mice fed a HF diet as compared to obese mice. PGC-1α is abundantly expressed in tissues with high energy demand [13, 47], and its induction, along with AMPK and SIRT1, regulates mitochondrial oxidative metabolism as well as mitochondrial biogenesis [52, 53, 55]. Thus, PGC-1α is critical in the activation of mitochondrial function including quality control, fusion potential, thermogenesis, and energy expenditure.

PGC-1α, UCP1, TFAM, and HO-1 levels were increased in adipose tissue of mice treated with EET-A, thus signifying a role of EETs in thermogenesis and browning of adipose tissue, which is masterly regulated via PGC-1α activation [52, 53, 56], EET-mediated induction of PGC-1α and HO-1 favors an increase in mitochondrial fusion, biogenesis, and OXPHOS, thereby providing metabolic protection in HF diet induced obesity in mice; this finding is supported by recent reports by us and others showing that HO-1 regulates mitochondrial function, quality control, biogenesis, and dynamics [46, 57, 58].

Regardless of the duration of treatment, EET-A reduced HF diet induced weight gain while normalizing blood glucose levels, thus confirming the beneficial EET-mediated effects in diet-induced obesity [8, 11, 59]. The restoration of the metabolic parameters was mirrored by the normalization of the adipogenic markers FAS, pP2, PEGI/MEST, and C/EBPα, as well as the reduction of inflammation (TNFα and IL-6) in visceral fat obtained from EET-A-treated mice fed a HF diet as compared to the obese control mice. The normalization of adipogenic and inflammatory markers in HF diet fed mice treated with EET-A was coupled with increased levels of adiponectin and HO-1, both key to the maintenance of adipocyte maturation in favor of early-stage adipocyte differentiation, that is, healthy adipocytes [8, 58, 60–62].

The present study is of substantial interest from both a basic and a clinical science perspective, defining the existence of an EET-PGC-1α-HO-1 regulatory axis that can ameliorate the deleterious effects of HF diet-induced metabolic abnormalities, including insulin resistance, and prediabetic conditions involving adipose tissues. A deeper understanding of the mode of action of EET-PGC-1α axis necessary to maintain mitochondrial dynamics by favoring fusion over fission, increased insulin sensitivity, and improved energy expenditure will, we believe, provide new approaches in the treatment of obesity and metabolic syndrome associated complications, including insulin resistance, and subsequent cardiovascular complications. We consider the metabolically favorable interaction of lipid mediators generated by CYP450 epoxygenase that provide the potential of therapeutic targeting of the mitochondria dynamics in order to increase fusion over fission potential and other mitochondrial associated parameters that are dependent upon PGC-1α expression. This approach offers a portal to the treatment of metabolic diseases and hypertension with the result of an improved outcome in what is acknowledged to be a global epidemic of obesity.

Disclosure
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Competing Interests
There is no conflict of interests among the authors.

Authors’ Contributions
Shailendra P. Singh performed experiments and provided methods; Lars Bellner performed experiments, collected literature citations, and edited manuscript; Luca Vanella performed experiments and helped write discussion; Nader G. Abraham planned and designed the experimental protocol and wrote first draft of manuscript; Jian Cao designed PGC1α sequence; and John R. Falck designed and provided EET-A and other agonists.
Acknowledgments

This work was supported by National Institutes of Health Grants HL34300 and HL55601, the Brickstreet Foundation, the Huntington Foundation (Nader G. Abraham), and gifts from the Renfield Foundation to The Rockefeller University (Attallah Kappas). The authors wish to thank Dr. G. Drummond for his excellent reviewing of the scientific content and Mrs. Jennifer Brown, Department of Pharmacology, New York Medical College, for her outstanding editorial assistance in the preparation of the manuscript.

References


